• Don't get left out, we need you to opt in - GDPR

    NRAS News | 14 May 2018

    The European Union has taken a monumental step in protecting the fundamental right to privacy for every EU resident with the General Data Protection Regulation (GDPR) which will be effective from May 25, 2018.

  • Apni Jung अपनी जंग

    NRAS News | 26 Apr 2018

    There is a big social stigma around Rheumatoid Arthritis (and other long term conditions) in South Asian communities! Research suggests South Asian people with RA are often forced to hide their condition due to society beliefs, misconceptions etc. Combined with language barriers, this can have a severe impact on their ability to receive accurate info and live a healthy life.

  • Biosimilars and Rheumatoid Arthritis | Making the switch

    RA news | 23 Mar 2018

    The Oxford Academic Health Science Network (Oxford AHSN) and Sandoz, have developed an informative animation on biosimilars with input from individuals living with inflammatory arthritis and in partnership with the National Rheumatoid Arthritis Society.

  • Sanofi and NRAS launch "RefRAme the Future"

    21 Mar 2018

    A new campaign that highlights the importance of mental strength in helping people with RA manage their condition

  • Love Your Heart

    NRAS News | 14 Feb 2018

    NRAS Launches 'Love Your Heart' Interactive Video Programme. A new initiative aims to decrease cardiovascular risk for people with Rheumatoid Arthritis.

  • NRAS welcomes review of PIP assessments

    RA news | 2 Feb 2018

    Earlier this week, the Department for Work and Pensions (DWP) announced that every person receiving Personal Independence Payments (PIP) will have their claim reviewed. This follows a court ruling that said changes to PIP were unfair to people with mental health conditions.

  • Looking after yourself this flu season

    RA news | 26 Jan 2018

    Getting an annual flu vaccine is recommended for people with RA, but if you do develop flu or live with someone who has it, the following advice issued to patients by Portsmouth Hospital’s Department of Rheumatology may be useful to you.

  • CIMZIA® label change marks an important advance for women in the UK of childbearing age with moderate to severe active rheumatoid arthritis

    RA news | 15 Jan 2018

    The European Medicines Agency (EMA) has approved the label change for UCB’s CIMZIA® (certolizumab pegol), making it the first anti-TNF for potential use in women with moderate to severe active rheumatoid arthritis, active psoriatic arthritis and ankylosing spondylitis during both pregnancy and breastfeeding.

View news archive